Abstract |
The effects of the farnesyl transferase inhibitor FTI-778,123 on the proliferation of normal, MDS, AML, and CML hemopoietic progenitor cells was studied. MDS myeloid and erythroid progenitors are significantly more sensitive to FTI than normal progenitors while AML myeloid progenitors may be somewhat more sensitive than normal progenitors. In contrast, no difference between CML and normal progenitors are detectable. These data strongly suggest that a trial of this agent in patients with MDS and perhaps in patients with AML is indicated.
|
Authors | X K Huang, P Meyer, B Li, A Raza, H D Preisler |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 44
Issue 1
Pg. 157-64
(Jan 2003)
ISSN: 1042-8194 [Print] United States |
PMID | 12691158
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Enzyme Inhibitors
- Imidazoles
- L 778,123
- Alkyl and Aryl Transferases
- Farnesyltranstransferase
|
Topics |
- Alkyl and Aryl Transferases
(antagonists & inhibitors)
- Antineoplastic Agents
(pharmacology)
- Bone Marrow Cells
(drug effects, pathology)
- Case-Control Studies
- Cell Division
(drug effects)
- Dose-Response Relationship, Drug
- Enzyme Inhibitors
(pharmacology)
- Farnesyltranstransferase
- Humans
- Imidazoles
(pharmacology)
- Leukemia, Myeloid
(drug therapy, pathology)
- Myelodysplastic Syndromes
(drug therapy, pathology)
- Neoplastic Stem Cells
(drug effects, pathology)
|